Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis

奥马佐单抗 医学 荟萃分析 不利影响 安慰剂 随机对照试验 严格标准化平均差 内科学 生活质量(医疗保健) 最小临床重要差异 系统回顾 免疫球蛋白E 人口 梅德林 免疫学 抗体 替代医学 病理 护理部 法学 环境卫生 政治学
作者
Sophia Tsabouri,George Ntritsos,Fotios Koskeridis,Εvangelos Εvangelou,Petter Olsson,Κonstantinos Κostikas
出处
期刊:Rhinology [European Rhinologic Society]
被引量:26
标识
DOI:10.4193/rhin21.159
摘要

Background: Allergic rhinitis (AR), an IgE mediated inflammatory disease, significantly impacts quality of life of a considerable proportion of the general population. Omalizumab, a humanized monoclonal antibody against IgE, has been evaluated for both seasonal and perennial AR. We aimed to assess the efficacy and safety of omalizumab in randomized controlled trials (RCTs) in inadequately controlled AR. Methods: We conducted a systematic literature search of RCTs evaluating the safety and efficacy of omalizumab in AR. We synthesized evidence for clinical improvement of AR symptoms, quality of life, reduction of the use of rescue medication, and adverse events. Results: The systematic search returned 289 articles, of which 12 RCTs were eligible for data extraction and meta-analysis. Omalizumab reduced the Daily Nasal Symptom Severity Score (DNSSS) by a summary standardized mean difference of -0.41 points with large heterogeneity; omalizumab significantly reduced the DNSSS both in the 3 cedar pollen-induced AR trials by -0.97 points and to a lower extent in the remaining five non-cedar trials by -0.19 points. Omalizumab also improved the Daily Ocular Symptom Severity Score (DOSSS) by a summary standardized mean difference of -0.30 points with large heterogeneity; the Rhino-conjunctivitis Quality of Life Questionnaire by a summary standardized mean difference of -0.45 points with no heterogeneity and the mean daily consumption of rescue antihistamines by a summary standardized mean difference of -0.21 with large heterogeneity. No statistically significant difference in the occurrence of adverse events was observed between omalizumab and placebo. Conclusion: Our findings further support the efficacy and safety of omalizumab in the management of patients with allergic rhinitis inadequately controlled with a conventional treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
诡异的饭团完成签到,获得积分10
刚刚
anan完成签到 ,获得积分10
1秒前
常绝山完成签到 ,获得积分10
1秒前
幽默皮皮虾完成签到,获得积分10
1秒前
易止完成签到 ,获得积分10
1秒前
just完成签到,获得积分10
2秒前
4秒前
Disguise完成签到,获得积分10
4秒前
Young4399完成签到 ,获得积分10
4秒前
火星上宛秋完成签到 ,获得积分10
5秒前
5秒前
5秒前
量子星尘发布了新的文献求助10
5秒前
szh123完成签到 ,获得积分10
6秒前
Luke发布了新的文献求助10
8秒前
mauve完成签到 ,获得积分10
8秒前
丽丽完成签到,获得积分10
12秒前
敏感笑槐完成签到 ,获得积分10
13秒前
Luke完成签到,获得积分10
13秒前
得鹿梦鱼完成签到,获得积分10
14秒前
嗝嗝完成签到,获得积分10
16秒前
Perry应助科研通管家采纳,获得30
16秒前
16秒前
今后应助水晶茶杯采纳,获得10
16秒前
peterlzb1234567完成签到,获得积分10
18秒前
natsu401完成签到 ,获得积分10
21秒前
mmddlj完成签到 ,获得积分10
21秒前
健康的雁凡完成签到,获得积分10
21秒前
稳重完成签到 ,获得积分10
23秒前
26秒前
haiqi完成签到,获得积分20
30秒前
白智妍发布了新的文献求助10
31秒前
王叮叮完成签到,获得积分10
32秒前
jeronimo完成签到,获得积分10
33秒前
33秒前
pcr163应助大橙子采纳,获得150
36秒前
李燕发布了新的文献求助10
38秒前
道友等等我完成签到,获得积分0
38秒前
狂野乌冬面完成签到 ,获得积分10
42秒前
xinglin完成签到 ,获得积分10
44秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022